Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever
ORPHANET JOURNAL OF RARE DISEASES, cilt.12, 2017 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 12
- Basım Tarihi: 2017
- Doi Numarası: 10.1186/s13023-017-0642-0
- Dergi Adı: ORPHANET JOURNAL OF RARE DISEASES
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır
Özet
Background: There is no established treatment of AA amyloidosis, a long-term complication of various chronic inflammatory diseases associated with increased mortality, such as familial Mediterranian fever (FMF). Recently there are few reports pointing out that tocilizumab(TCZ), an anti IL-6 agent may be effective in AA amyloidosis resistant to conventional treatments. We report our data on the effect of TCZ in patients with FMF complicated with AA amyloidosis.